Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 870 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cognition Function Clear all

Conditions: Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Choriocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Dysgerminoma, Ovarian Embryonal Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Germ Cell Tumor, Ovarian Mucinous Cystadenocarcinoma, Ovarian Polyembryoma, Ovarian Sarcoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Teratoma, Ovarian Yolk Sac Tumor, Stage I Ovarian Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions: Cognitive Assessment, Quality-of-Life Assessment; Procedure · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 182
States / cities: Tucson, Arizona • Little Rock, Arkansas • Burbank, California + 129 more

Conditions: Alzheimer's Disease
Interventions: Simvastatin, L-Arginine, Tetrahydrobiopterin; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 55 Years to 85 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Depression in Adolescence, Adverse Childhood Experiences
Interventions: FIRST: Repairing Thoughts; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years to 15 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cardiovascular Diseases
Interventions: Nutrition, Exercise, Stress Management Counseling, usual care; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 45 Years to 75 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections, Neurologic Disorders
Interventions: Anakinra; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 61 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Baltimore, Maryland • Bethesda, Maryland

Conditions: MDMA Discontinuation Syndrome
Interventions: 3,4-methylenedioxymethamphetamine or Placebo; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cognitive Function, Healthy
Interventions: Resting State Indirect Calorimetry, ApoE, Metabolism, Cognitive Challenge; Other · Genetic · Diagnostic Test
Lead sponsor: Lance Johnson; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Cognitive Performance, Age-Related Macular Degeneration, Bone Loss
Interventions: Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF), Placebo Comparator; Dietary Supplement
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Breast Cancer Survivors
Interventions: Traditional Neurocognitive Assessments, Online Cognitive Battery (Cogsuite); Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 441 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: Montreal Cognitive Assessment (MoCA); Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Healthy
Interventions: Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Mild Traumatic Brain Injury (mTBI), Sports-related Concussion, Heart Rate Variability (HRV), Walking, Oculomotor, Saliva, Exosomal microRNA, Cognitive Function
Interventions: Home-Based Mobile Dual-Task Intervention (BraW-Day™); Behavioral
Lead sponsor: Hyunhwa Lee; Other
Eligibility: 18 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Breast Cancer
Interventions: Aerobic Exercise and Relaxation, Aerobic Exercise Only, Relaxation Only; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Brain Tumors, Nervous System Tumors, Cognition Disorders, Fatigue
Interventions: Armodafinil, placebo; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: Lighting Intervention; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 50 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Albany, New York • New York, New York

Conditions: Older Adults, Physical Function, Cognitive Function
Interventions: Curcumin, microcrystalline cellulose; Drug
Lead sponsor: University of Florida; Other
Eligibility: 65 Years to 99 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Menopause, Sleep Disturbance, Anxiety, Depression, Cognitive Function, Fatigue, Libido
Interventions: Radicle Revive Placebo Control Form 4.1, Radicle Revive Active Study Product 4.1 Usage; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Panhypopituitarism
Interventions: Not listed
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 55 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Genotype, Allelic Frequencies of Genetic Markers, Brain Mapping, Brain Disease, fMRI
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years and older
Enrollment: 2,802 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1991 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bipolar Disorder
Interventions: lurasidone, Placebo; Drug · Other
Lead sponsor: Lakshmi N Yatham; Other
Eligibility: 19 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts • Cleveland, Ohio

Conditions: Schizophrenia
Interventions: Aerobic Exercise, Standard Psychiatric Treatment; Behavioral · Other
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Respiratory Tract Infection, Smell Disorder, Influenza, Rhinosinusitis, COVID-19, Depression, Parosmia, Hyposomia, Normosomia, Anosmia
Interventions: Not listed
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aging
Interventions: Nicotinamide riboside, Placebo; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 60 Years to 85 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Minimal Hepatic Encephalopathy
Interventions: Lactulose, placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years to 18 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Endothelial Facilitation in Alzheimer's Disease

Life Experiences in Adolescents and the Development of Skills

Novel Strategies for Reducing Heart Disease Risk Disparities

Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection

Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.

Apolipoprotein E (ApoE) and Metabolism

Lutein, Zeaxathin, and Fish Oil Supplementation

Evaluation of an Online, Remote Cognitive Battery for Use in Cancer Survivorship

Serial Testing To Assess Cognitive Function In Cancer

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

Mobile Dual-Task Brain and Balance Intervention for Concussion Recovery

Responsiveness to Acute Changes in Exercise and Relaxation (RACER) Trial

Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors

The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment

Curcumin and Function in Older Adults

Radicle Revive 24: A Study of Health and Wellness Products on Menopausal Health and Related Health Outcomes

Baseline Sexual Function, Cognitive Function, Body Composition and Muscle Parameters and Pharmacokinetics of Transdermal Testosterone Gel in Women With Hypopituitarism

Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers

Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.

Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

The Effect of NAD Supplementation on Brain Vascular Health in Aging

Study of Lactulose in Children With Chronic Liver Disease